R&D ARTICLES

• Working With The U.S Army To Achieve Tech Transfer Success

  Many pharmas or biotechs may not know the opportunities available from working with the U.S. Army on license agreements or Collaborative Research and Development Agreements (CRADAs). Here’s what to know about the Medical Technology Transfer (MTT) office.

• Leadership Competencies For Rare Disease Therapies

  Traditionally, firms seek out leadership candidates who are strong "cultural fits." In the case of Big Pharma hiring experts in gene and cell therapies, however, they should be looking for "misfits" if you will.

• Meeting Business Challenges By Design, Not Accident

  The story of the business challenges faced by Diasome Pharmaceuticals as it develops its insulin-enhancing delivery technology, which seeks to correct a long-known deficiency in subcutaneous injection of insulin.

• The Unique Challenges Facing Cannabis-based Pharma

  Now that the FDA has finally approved the first-ever pharmaceutical derived from the cannabis plant, will drug development — and success — in this niche finally take off?

• Germany’s Plan To Foster And Grow Biopharma Innovation

  In Germany, bioclusters and technology parks have been created to encourage and support pharmaceutical innovation in the region.

• Biopharma Bringing RWE Into The Real World

  Real-world evidence is playing an increasingly important role throughout the drug development lifecycle—as outlined in Deloitte's latest survey on the life sciences industry's RWE capabilities— and companies are really beginning to take notice.

• J&J’s QuickFire Challenges: Crowdsourcing Innovation

  An in-depth look at J&J’s QuickFire Challenge program and how some of the winners have benefitted (and grown) beyond the cash grants.

• 3 Operating Principles For Successful Drug Development

  Can a culture with supporting systems that are simple, efficient, and effective significantly shorten drug development times? Why not?

• Can A P3 Reduce Attrition Of Drug Candidates?

  A look at a unique UK-based public-private partnership (P3), called Open Targets that was created to help companies choose better drug targets and reduce attrition of candidate drugs.

• Intricate Supply Chain Complicates Gene Therapy Manufacturing

  With the FDA’s approval of three new gene therapies, researchers and manufacturers must now figure out how streamline the development process.